These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 15331914

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.
    Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ.
    J Pharm Sci; 2003 Oct; 92(10):2082-9. PubMed ID: 14502547
    [Abstract] [Full Text] [Related]

  • 3. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
    Tang C, Kuo Y, Pudvah NT, Ellis JD, Michener MS, Egbertson M, Graham SL, Cook JJ, Hochman JH, Prueksaritanont T.
    Biochem Pharmacol; 2009 Sep 15; 78(6):642-7. PubMed ID: 19481060
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC, Maurer TS, Pollack GM.
    Drug Metab Dispos; 2007 Apr 15; 35(4):660-6. PubMed ID: 17237155
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein.
    Obradovic T, Dobson GG, Shingaki T, Kungu T, Hidalgo IJ.
    Pharm Res; 2007 Feb 15; 24(2):318-27. PubMed ID: 17180728
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
    He H, Lyons KA, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro GM, Cohen LH, Tang W.
    Xenobiotica; 2009 Sep 15; 39(9):687-93. PubMed ID: 19569734
    [Abstract] [Full Text] [Related]

  • 13. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM.
    Drug Metab Dispos; 2008 Feb 15; 36(2):268-75. PubMed ID: 17962372
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
    Peng SX, Ritchie DM, Cousineau M, Danser E, Dewire R, Floden J.
    J Pharm Sci; 2006 Sep 15; 95(9):1984-93. PubMed ID: 16850393
    [Abstract] [Full Text] [Related]

  • 16. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
    Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD.
    FEBS J; 2007 Dec 15; 274(23):6204-14. PubMed ID: 17986257
    [Abstract] [Full Text] [Related]

  • 17. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ, Sandmann S, Engel K, Radtke M.
    Drug Metab Dispos; 2010 Aug 15; 38(8):1341-6. PubMed ID: 20413726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.